# Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

> **NCT02228382** · PHASE4 · TERMINATED · sponsor: **Pfizer** · enrollment: 163 (actual)

## Conditions studied

- Previously Treated PH + CML

## Interventions

- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT02228382
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11-07
- **Primary completion:** 2020-10-13
- **Final completion:** 2020-10-13
- **Target enrollment:** 163 (ACTUAL)
- **Last updated:** 2021-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228382, "Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02228382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*